PCM
KIN

Prelude Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Prelude Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$1K – 2221
2020
Q3 		$1K Hold
200
– – ﹤0.01% 1752
2020
Q2 		$1K Buy
+200
New +$894 ﹤0.01% 1907
2019
Q3 		– Sell
-1,993
Closed -$17K – 2217
2019
Q2 		$17K Buy
+1,993
New +$17.2K ﹤0.01% 1320

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's KIN Position: Q4 2020 in Review

Prelude Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q4 2020, closing a stake of 200 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in KIN in Q2 2019 and held it in 3 quarters. The position peaked at $17K in Q2 2019. 82 funds tracked by Wall St. Rank hold KIN as of Q4 2020.

  • Prelude Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 200 Kindred Biosciences, Inc. shares in Q4 2020, an estimated $1K.
  • Prelude Capital Management first reported a position in Kindred Biosciences, Inc. in Q2 2019 and held it in 3 quarters.
  • Prelude Capital Management's Kindred Biosciences, Inc. position peaked at $17K in Q2 2019.
  • 82 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.